RAKGEORRECNew Pharmacotherapy Combined with RECOVERYTRSGR and RECOVERYTRSBDGR Programs for Treatment-Resistant Schizophrenia and Bipolar Disorder
This clinical trial aims to evaluate the effectiveness of a new pharmacotherapy in combination with the RECOVERYTRSGR and RECOVERYTRSBDGR programs for treating adults with treatment-resistant schizophrenia or bipolar disorder, by measuring various cognitive and psychological symptoms.
Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),
+ Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,
+ Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine
Schizophrenia, Treatment-Resistant+1
+ Mental Disorders
+ Schizophrenia
Treatment Study
Summary
Study start date: June 4, 2025
Actual date on which the first participant was enrolled.This study focuses on improving treatment options for individuals with difficult-to-treat mental health conditions: treatment-resistant schizophrenia and treatment-resistant bipolar disorder. These are challenging conditions that require long-term care, and traditional treatments often do not provide enough relief. The study investigates the effectiveness of combining medication with two new programs, RECOVERYTRSGR for schizophrenia and RECOVERYTRSBDGR for bipolar disorder. These programs integrate medication, cognitive behavioral therapy, and rehabilitation to enhance mental recovery, improve cognitive functions, reduce symptoms, and improve daily functioning. Participants in this study undergo a combination of pharmacotherapy, which involves taking prescribed medication, and engaging in cognitive behavioral psychotherapy and rehabilitation. These interventions are designed to be long-term, providing ongoing support to help manage and potentially improve their condition. Although the study does not specify the exact outcomes measured, it aims to track improvements in cognition, symptom relief, and overall functional recovery. The study does not mention specific risks or side effects, but participants can potentially benefit from a comprehensive approach that targets multiple aspects of their mental health.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.40 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.4 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalGroup II
Active ComparatorGroup III
ExperimentalGroup IV
Active ComparatorStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Private practice of Dr. S. Rakitzi and Dr. P. Georgila ILISION 34 15771 ATHENS GREECE
Athens, GreeceOpen Private practice of Dr. S. Rakitzi and Dr. P. Georgila ILISION 34 15771 ATHENS GREECE in Google Maps